AG˹ٷ

STOCK TITAN

[8-K] Viking Therapeutics, Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Atlassian (TEAM) Form 4: CEO, co-founder and 10% owner Michael Cannon-Brookes sold a total of 7,765 Class A shares on 22 Jul 2025 under a pre-arranged Rule 10b5-1 plan adopted 20 Feb 2025.

The stock was disposed of in seven separate trades at weighted-average prices between $195.965 and $202.35, generating roughly $1.55 million in gross proceeds. Following the sales, the insider—through CBC Co Pty Ltd as trustee of the Cannon-Brookes Head Trust—continues to hold 375,585 Class A shares, maintaining more than 98% of his prior indirect position and his 10% beneficial-owner status.

No derivative activity or purchases were reported. Given the modest 2% reduction in holdings and the existence of a 10b5-1 plan, the transactions appear routine and are unlikely to materially alter insider alignment, though any CEO liquidation can create short-term sentiment pressure.

Atlassian (TEAM) Modulo 4: Il CEO, co-fondatore e proprietario del 10% Michael Cannon-Brookes ha venduto un totale di 7.765 azioni di Classe A il 22 luglio 2025, nell’ambito di un piano predefinito secondo la regola 10b5-1 adottato il 20 febbraio 2025.

Le azioni sono state cedute in sette operazioni separate a prezzi medi ponderati compresi tra 195,965 e 202,35 dollari, generando circa 1,55 milioni di dollari di ricavi lordi. Dopo le vendite, l’insider � tramite CBC Co Pty Ltd in qualità di trustee del Cannon-Brookes Head Trust � detiene ancora 375.585 azioni di Classe A, mantenendo oltre il 98% della sua precedente posizione indiretta e il suo status di proprietario beneficiario del 10%.

Non sono state segnalate attività su derivati né acquisti. Considerata la riduzione modesta del 2% nelle partecipazioni e l’esistenza di un piano 10b5-1, le operazioni sembrano di routine e difficilmente modificheranno in modo significativo l’allineamento degli insider, anche se qualsiasi liquidazione da parte del CEO può generare pressioni sul sentiment nel breve termine.

Atlassian (TEAM) Formulario 4: El CEO, cofundador y propietario del 10%, Michael Cannon-Brookes, vendió un total de 7.765 acciones Clase A el 22 de julio de 2025, bajo un plan preestablecido según la regla 10b5-1 adoptado el 20 de febrero de 2025.

Las acciones se vendieron en siete transacciones separadas a precios promedio ponderados entre 195,965 y 202,35 dólares, generando aproximadamente 1,55 millones de dólares en ingresos brutos. Tras las ventas, el insider —a través de CBC Co Pty Ltd como fiduciario del Cannon-Brookes Head Trust� continúa poseyendo 375.585 acciones Clase A, manteniendo más del 98% de su posición indirecta previa y su estatus como propietario beneficiario del 10%.

No se reportaron actividades con derivados ni compras. Dada la modesta reducción del 2% en las participaciones y la existencia de un plan 10b5-1, las transacciones parecen rutinarias y es poco probable que alteren significativamente la alineación de los insiders, aunque cualquier liquidación por parte del CEO puede generar presión en el sentimiento a corto plazo.

Atlassian (TEAM) 양식 4: CEO이자 공동 창립자이� 10% 지� 보유자인 Michael Cannon-Brookes가 2025� 7� 22� 사전 승인� 10b5-1 규칙 계획� 따라 � 7,765� 클래� A 주식� 매도했습니다. � 계획은 2025� 2� 20일에 채택되었습니�.

주식은 7번에 걸쳐 각각 가� 평균 가� $195.965에서 $202.35 사이� 매도되어 � 155� 달러� � 수익� 창출했습니다. 매도 �, 내부자는 CBC Co Pty Ltd� 신탁자로 하는 Cannon-Brookes Head Trust� 통해 여전� 375,585� 클래� A 주식� 보유하고 있으�, 이전 간접 지분의 98% 이상� 10%� 실질 소유� 지위를 유지하고 있습니다.

파생상품 거래� 매수� 보고되지 않았습니�. 보유 지분이 2% 정도� 줄었� 10b5-1 계획� 존재한다� 점을 고려� �, 이번 거래� 일상적인 것으� 보이� 내부� 정렬� � 변화를 주지� 않을 것으� 보입니다. 다만 CEO� 주식 매도� 단기적으� 시장 심리� 압박� � � 있습니다.

Atlassian (TEAM) Formulaire 4 : Le PDG, cofondateur et propriétaire de 10 % Michael Cannon-Brookes a vendu un total de 7 765 actions de classe A le 22 juillet 2025, dans le cadre d’un plan préétabli selon la règle 10b5-1 adopté le 20 février 2025.

Les actions ont été cédées en sept transactions distinctes à des prix moyens pondérés compris entre 195,965 et 202,35 dollars, générant environ 1,55 million de dollars de produit brut. Après ces ventes, l’initié � via CBC Co Pty Ltd en tant que fiduciaire du Cannon-Brookes Head Trust � détient toujours 375 585 actions de classe A, conservant plus de 98 % de sa position indirecte antérieure ainsi que son statut de propriétaire bénéficiaire à hauteur de 10 %.

Aucune activité sur dérivés ni achat n’a été signalé. Étant donné la réduction modérée de 2 % des avoirs et l’existence d’un plan 10b5-1, ces transactions semblent routinières et ne devraient pas modifier de manière significative l’alignement des initiés, bien que toute liquidation par le PDG puisse exercer une pression sur le sentiment à court terme.

Atlassian (TEAM) Formular 4: CEO, Mitgründer und 10%-Eigentümer Michael Cannon-Brookes verkaufte am 22. Juli 2025 insgesamt 7.765 Aktien der Klasse A im Rahmen eines vorab vereinbarten Rule 10b5-1-Plans, der am 20. Februar 2025 angenommen wurde.

Die Aktien wurden in sieben separaten Transaktionen zu gewichteten Durchschnittspreisen zwischen 195,965 und 202,35 US-Dollar veräußert, was etwa 1,55 Millionen US-Dollar Bruttoerlös einbrachte. Nach den Verkäufen hält der Insider � über CBC Co Pty Ltd als Treuhänder des Cannon-Brookes Head Trust � weiterhin 375.585 Aktien der Klasse A und bewahrt damit über 98 % seiner vorherigen indirekten Position sowie seinen 10%-Eigentümerstatus.

Keine Derivataktivitäten oder Käufe wurden gemeldet. Angesichts der moderaten Reduzierung um 2 % und der Existenz eines 10b5-1-Plans erscheinen die Transaktionen routinemäßig und werden die Insider-Ausrichtung voraussichtlich nicht wesentlich verändern, auch wenn eine CEO-Veräußerung kurzfristig den Marktstimmungsdruck erhöhen kann.

Positive
  • Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic timing.
  • Insider retains 375,585 shares, maintaining substantial equity alignment with shareholders.
Negative
  • CEO liquidated 7,765 shares worth �$1.55 m, which could cause minor negative sentiment.
  • No offsetting insider purchases were disclosed in the period.

Insights

TL;DR: Small, pre-planned CEO sale; negligible impact on ownership or thesis.

The 7,765-share sale represents ~2% of Cannon-Brookes� stake and less than 0.3% of daily TEAM volume, limiting market impact. Proceeds of ~$1.55 m are immaterial relative to his remaining ~$75 m holding. Executed under a February-adopted 10b5-1 plan, the transaction reduces signaling risk. From a valuation standpoint, the filing does not change cash flow, guidance, or strategic outlook; therefore I view the development as neutral.

TL;DR: Governance-compliant sale; insider still strongly aligned.

The filing demonstrates adherence to SEC Rule 10b5-1 best practices, with full price ranges disclosed and trustee ownership clarified. Retention of 375,585 shares preserves significant skin-in-the-game, supporting shareholder alignment. While any director sale draws attention, the minimal size and structured plan suggest routine liquidity rather than adverse insider insight. I classify the event as governance-neutral.

Atlassian (TEAM) Modulo 4: Il CEO, co-fondatore e proprietario del 10% Michael Cannon-Brookes ha venduto un totale di 7.765 azioni di Classe A il 22 luglio 2025, nell’ambito di un piano predefinito secondo la regola 10b5-1 adottato il 20 febbraio 2025.

Le azioni sono state cedute in sette operazioni separate a prezzi medi ponderati compresi tra 195,965 e 202,35 dollari, generando circa 1,55 milioni di dollari di ricavi lordi. Dopo le vendite, l’insider � tramite CBC Co Pty Ltd in qualità di trustee del Cannon-Brookes Head Trust � detiene ancora 375.585 azioni di Classe A, mantenendo oltre il 98% della sua precedente posizione indiretta e il suo status di proprietario beneficiario del 10%.

Non sono state segnalate attività su derivati né acquisti. Considerata la riduzione modesta del 2% nelle partecipazioni e l’esistenza di un piano 10b5-1, le operazioni sembrano di routine e difficilmente modificheranno in modo significativo l’allineamento degli insider, anche se qualsiasi liquidazione da parte del CEO può generare pressioni sul sentiment nel breve termine.

Atlassian (TEAM) Formulario 4: El CEO, cofundador y propietario del 10%, Michael Cannon-Brookes, vendió un total de 7.765 acciones Clase A el 22 de julio de 2025, bajo un plan preestablecido según la regla 10b5-1 adoptado el 20 de febrero de 2025.

Las acciones se vendieron en siete transacciones separadas a precios promedio ponderados entre 195,965 y 202,35 dólares, generando aproximadamente 1,55 millones de dólares en ingresos brutos. Tras las ventas, el insider —a través de CBC Co Pty Ltd como fiduciario del Cannon-Brookes Head Trust� continúa poseyendo 375.585 acciones Clase A, manteniendo más del 98% de su posición indirecta previa y su estatus como propietario beneficiario del 10%.

No se reportaron actividades con derivados ni compras. Dada la modesta reducción del 2% en las participaciones y la existencia de un plan 10b5-1, las transacciones parecen rutinarias y es poco probable que alteren significativamente la alineación de los insiders, aunque cualquier liquidación por parte del CEO puede generar presión en el sentimiento a corto plazo.

Atlassian (TEAM) 양식 4: CEO이자 공동 창립자이� 10% 지� 보유자인 Michael Cannon-Brookes가 2025� 7� 22� 사전 승인� 10b5-1 규칙 계획� 따라 � 7,765� 클래� A 주식� 매도했습니다. � 계획은 2025� 2� 20일에 채택되었습니�.

주식은 7번에 걸쳐 각각 가� 평균 가� $195.965에서 $202.35 사이� 매도되어 � 155� 달러� � 수익� 창출했습니다. 매도 �, 내부자는 CBC Co Pty Ltd� 신탁자로 하는 Cannon-Brookes Head Trust� 통해 여전� 375,585� 클래� A 주식� 보유하고 있으�, 이전 간접 지분의 98% 이상� 10%� 실질 소유� 지위를 유지하고 있습니다.

파생상품 거래� 매수� 보고되지 않았습니�. 보유 지분이 2% 정도� 줄었� 10b5-1 계획� 존재한다� 점을 고려� �, 이번 거래� 일상적인 것으� 보이� 내부� 정렬� � 변화를 주지� 않을 것으� 보입니다. 다만 CEO� 주식 매도� 단기적으� 시장 심리� 압박� � � 있습니다.

Atlassian (TEAM) Formulaire 4 : Le PDG, cofondateur et propriétaire de 10 % Michael Cannon-Brookes a vendu un total de 7 765 actions de classe A le 22 juillet 2025, dans le cadre d’un plan préétabli selon la règle 10b5-1 adopté le 20 février 2025.

Les actions ont été cédées en sept transactions distinctes à des prix moyens pondérés compris entre 195,965 et 202,35 dollars, générant environ 1,55 million de dollars de produit brut. Après ces ventes, l’initié � via CBC Co Pty Ltd en tant que fiduciaire du Cannon-Brookes Head Trust � détient toujours 375 585 actions de classe A, conservant plus de 98 % de sa position indirecte antérieure ainsi que son statut de propriétaire bénéficiaire à hauteur de 10 %.

Aucune activité sur dérivés ni achat n’a été signalé. Étant donné la réduction modérée de 2 % des avoirs et l’existence d’un plan 10b5-1, ces transactions semblent routinières et ne devraient pas modifier de manière significative l’alignement des initiés, bien que toute liquidation par le PDG puisse exercer une pression sur le sentiment à court terme.

Atlassian (TEAM) Formular 4: CEO, Mitgründer und 10%-Eigentümer Michael Cannon-Brookes verkaufte am 22. Juli 2025 insgesamt 7.765 Aktien der Klasse A im Rahmen eines vorab vereinbarten Rule 10b5-1-Plans, der am 20. Februar 2025 angenommen wurde.

Die Aktien wurden in sieben separaten Transaktionen zu gewichteten Durchschnittspreisen zwischen 195,965 und 202,35 US-Dollar veräußert, was etwa 1,55 Millionen US-Dollar Bruttoerlös einbrachte. Nach den Verkäufen hält der Insider � über CBC Co Pty Ltd als Treuhänder des Cannon-Brookes Head Trust � weiterhin 375.585 Aktien der Klasse A und bewahrt damit über 98 % seiner vorherigen indirekten Position sowie seinen 10%-Eigentümerstatus.

Keine Derivataktivitäten oder Käufe wurden gemeldet. Angesichts der moderaten Reduzierung um 2 % und der Existenz eines 10b5-1-Plans erscheinen die Transaktionen routinemäßig und werden die Insider-Ausrichtung voraussichtlich nicht wesentlich verändern, auch wenn eine CEO-Veräußerung kurzfristig den Marktstimmungsdruck erhöhen kann.

0001607678false00016076782025-07-232025-07-23

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2025

 

 

Viking Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37355

46-1073877

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

9920 Pacific Heights Blvd, Suite 350

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 704-4660

 

Viking Therapeutics, Inc.

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

VKTX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


In this report, “Viking Therapeutics,” “Viking,” “Company,” “we,” “us” and “our” refer to Viking Therapeutics, Inc.

Item 2.02 Results of Operations and Financial Condition.

On July 23, 2025, we issued a press release reporting our financial results for the second quarter ended June 30, 2025 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No

 

Description

99.1

 

Press release issued July 23, 2025, reporting financial results for the second quarter ended June 30, 2025 and providing a corporate update.

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Viking Therapeutics, Inc.

 

 

 

 

Date:

July 23, 2025

By:

/s/ Brian Lian, Ph.D.

 

 

 

Brian Lian, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)

 


FAQ

How many Atlassian (TEAM) shares did CEO Michael Cannon-Brookes sell?

He sold 7,765 Class A shares on 22 Jul 2025.

What was the average sale price reported in the Form 4?

Weighted-average prices ranged from $195.965 to $202.35 per share.

How many TEAM shares does the insider still own after the transactions?

Cannon-Brookes indirectly holds 375,585 Class A shares through a trust.

Was the insider sale executed under a 10b5-1 trading plan?

Yes, the plan was adopted on 20 Feb 2025.

Did the filing report any derivative security transactions?

No; Table II shows no derivative activity.

What percentage of the insider’s holdings were sold?

Approximately 2% of his previous indirect stake.
Viking Therapeutics Inc

NASDAQ:VKTX

VKTX Rankings

VKTX Latest News

VKTX Latest SEC Filings

VKTX Stock Data

3.61B
109.39M
2.7%
74.24%
21.3%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO